| Patient number (%) |  | ||
---|---|---|---|---|
Characteristic | LG group | AG group | ALG group | Pvalue |
Patient treated | 10 | 16 | 16 | - |
Age | Â | Â | Â | - |
Median | 51.5 | 55 | 51.5 | Â |
Range | 27~75 | 23~71 | 34~87 | Â |
Sex | Â | Â | Â | 0.694 |
Male | 7(70%) | 9 (56.3%) | 11(68.8%) | Â |
Female | 3(30%) | 7 (43.7%) | 5(31.2%) | Â |
Primary tumor site | Â | Â | Â | 0.711 |
Gastro | 6 (60%) | 9 (56.3%) | 8(50%) | Â |
Small intestine | 2 (20%) | 4 (25%) | 3(18.8%) | Â |
Colon | 2 (20%) | 2 (12.5%) | 3(18.8%) | Â |
Rectum | 0 | 1 (6.2%) | 0 | Â |
Mesentery | 0 | 0 | 2(12.5%) | Â |
Recurrent-free time from surgery | Â | Â | Â | - |
Median (month) | 15.5 | 12 | 24 | Â |
Range (month) | 9~108 | 2~100 | 3~108 | Â |
ECOG performance status | Â | Â | Â | 0.815 |
0 | 3 (30%) | 4 (25%) | 6(37.5%) | Â |
1 | 6(60%) | 9 (56.3%) | 9(56.3%) | Â |
2 | 1 (10%) | 2 (12.5%) | 0 | Â |
3 | 0 | 1 (6.2%) | 1(6.2%) | Â |
Biomarker | Â | Â | Â | Â |
CD117 positive | 10 (100%) | 16 (100%) | 16(100%) | - |
CD34 positive | 7 (70%) | 12 (75%) | 14(87.5%) | 0.518 |
Aggressive behavior | Â | Â | Â | 0.492 |
Very low & low risk | 4(40%) | 4(25%) | 8(50%) | Â |
Intermediate risk | 2(20%) | 2(12.5%) | 3(18.8%) | Â |
High risk | 4(40%) | 10(62.5%) | 5(31.2%) | Â |